<DOC>
	<DOCNO>NCT00927355</DOCNO>
	<brief_summary>We prospectively study 2 group diabetic patient treat pioglitazone placebo 26 week . Bone marrow aspirate obtain patient baseline 26 week treatment , hBMCs isolate bone marrow aspiration . The ability hBMCs differentiate osteoblast adipocytes lineage compare treatment pioglitazone compare placebo . In parallel , clinical marker bone formation resorption well bone mineral density assess 26 week treatment . Primary endpoint study detection change number osteoblast adipocytes cultured hBMCs study group within group .</brief_summary>
	<brief_title>Effect Thiazolidinediones Human Bone</brief_title>
	<detailed_description>E2a . Screening : Prescreening electronic medical record use much possible reduce screen failure rate . Patients undergo full history ( special focus inclusion exclusion criterion ) , physical exam , blood draw . Lab work consist CBC , PT , PTT , CMP , HbA1c , PTH , serum beta-HCG female childbearing potential testosterone male . We measure 25 ( OH ) Vitamin D baseline completion study . E2b . Study visit Subjects admit Grady GCRC overnight fast initial visit 26 week . Study drug dispense initial visit . At initial visit 26 week , subject undergo bone marrow aspiration skilled certified Hematology Oncology fellow , bone densitometry ( DXA ) hip spine , blood.draw ( 5mls ) . Subjects see follow-up Grady GCRC 2 week every 4 week thereafter measurement body weight , vital sign , target history look side effect study drug . Study drug dispense patient baseline monthly follow-up visit thereafter . To assess compliance , subject instruct return unused drug , subject take less 75 % study medication , patient withdrawn study . Patients monitor closely development side effect . Glycemic control assess HbA1c measurement baseline , 12 week study end study . Home blood sugar , fast occasional postprandial blood sugar assess study visit . E2b.2 . Bone Marrow Biopsy aspiration : Bone marrow ( BM ) aspiration do hematology oncology fellow , Dr. Simbo Aduloju , certify procedure Grady GCRC . Subjects pre-medicated 30 minute prior procedure oral Lorazepam 2mg Tylenol 500mg analgesia.The absolute contraindication BM aspiration presence bleeding disorder . During screen process , patient ask history coagulopathies hemophilia . In addition patient PT , PTT platelets checked baseline . Under sterile technique local anesthesia 2 % lidocaine , 5mls bone marrow aspirate posterior iliac crest use 16 gauge bone marrow aspiration needle attach 10 ml syringe . The sample place ice immediately transport lab Dr. George Beck . After procedure , manual pressure apply aspiration site minimum 5 minute prevent bleeding . Patients blood pressure check procedure prior departure GCRC ensure absence hypotension due lorazepam . E2b.2.1 . Please see section E2c . experimental design procurement hBMCs bone marrow aspirate determination osteoblast/adipocyte differentiation capacity hBMCs . E2b.3 . BMD Evaluation : DXA measurement perform spine dominant hip ( contralateral hip presence hardware dominant hip ) use GE Lunar Prodigy Instrument ( GE medical Systems ) Grady Memorial Hospital . The DXA scanner calibrate daily basis manufacturer 's phantom accord manufacturer guideline . Short-term root mean square coefficient variation center 1.1 % lumbar spine 1.5 % total hip . E2b.4 . Laboratory Assays : Bone formation marker ( osteocalcin , procollagen type-I N-terminal propeptide [ P1NP ] ) bone resorption marker ( β C-terminal telopeptide type 1 collagen [ β-CTX ] ) correlate strongly rate bone formation resorption respectively provide powerful data reflect average bone turnover globally across bone surface body . The disadvantage marker reflect final state time sample condition time point experiment . After overnight fast , serum assay subject 8 9 control diurnal variation . Blood sample collect processed nurse Grady GCRC core laboratory . Serum send lab Dr. George Beck store -80◦C . The following analysis do end study single batch marker . Please see table 2 detail assay .</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Subjects T2DM : naïve insulin TZD therapy On diet lifestyle therapy along submaximal metformin therapy HbA1c 7 % 8.0 % age 18 80 year gender Contraindications TZD therapy include congestive heart failure class III IV , and/or macular edema history osteoporosis ( T score &lt; 2.5 DXA scan ) osteoporotic fragility fracture treatment glucocorticoid within 1 year study enrollment treatment bisphosphonates , calcitriol , raloxifene , Calcitonin , estrogen vitamin D insufficiency , define 25 ( OH ) D level &lt; 30 ng/mL hyperparathyroidism liver disease ( LFTS &gt; 3x upper limit normal ) Kidney disease Cr &gt; 1.4 female Cr &gt; 1.5 male smoker ( active within month stop ) alcohol drug abuse/dependence hypogonadism male mental condition render subject unable understand scope study female subject pregnant breast feed chronic obstructive pulmonary disease obstructive sleep apnea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pioglitazone</keyword>
	<keyword>human bone marrow stem cell</keyword>
	<keyword>adipocytes</keyword>
	<keyword>osteoblast</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>adiponectin</keyword>
	<keyword>leptin</keyword>
	<keyword>CTX</keyword>
	<keyword>P1NP</keyword>
	<keyword>Osteocalcin</keyword>
</DOC>